DekaBank Deutsche Girozentrale Acquires New Shares in Enovis Co. (NYSE:ENOV)

DekaBank Deutsche Girozentrale bought a new position in shares of Enovis Co. (NYSE:ENOV) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,256 shares of the company’s stock, valued at approximately $55,000.

Several other large investors also recently bought and sold shares of the company. Scout Investments Inc. purchased a new stake in shares of Enovis in the 1st quarter worth about $6,116,000. Price T Rowe Associates Inc. MD raised its position in Enovis by 88.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock worth $23,802,000 after acquiring an additional 179,276 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Enovis by 100.6% in the first quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock valued at $23,606,000 after purchasing an additional 189,584 shares in the last quarter. First Eagle Investment Management LLC grew its position in shares of Enovis by 13.3% in the second quarter. First Eagle Investment Management LLC now owns 284,596 shares of the company’s stock valued at $12,864,000 after purchasing an additional 33,300 shares during the last quarter. Finally, Sei Investments Co. increased its stake in shares of Enovis by 50.9% during the 2nd quarter. Sei Investments Co. now owns 223,358 shares of the company’s stock worth $10,096,000 after purchasing an additional 75,317 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Evercore ISI decreased their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. Needham & Company LLC cut their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Finally, JMP Securities began coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Enovis Price Performance

ENOV opened at $42.43 on Monday. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03. The company’s 50 day simple moving average is $42.26 and its 200 day simple moving average is $45.79. The stock has a market capitalization of $2.37 billion, a PE ratio of -25.56 and a beta of 1.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.03. The company had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.61 EPS. As a group, sell-side analysts expect that Enovis Co. will post 2.7 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.